Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond

Fineline Cube Mar 30, 2026
Company Deals

Sinovac Biotech and Indonesia’s Bio Farma Forge Strategic Alliance to Expand Vaccine Access Across Developing Markets

Fineline Cube Mar 30, 2026
Company Deals

BrainAurora Medical Partners with Tokyo Lifestyle to Launch AI-Powered Digital Health Platform for Elderly Cognitive Care Across Asia

Fineline Cube Mar 30, 2026
Company Deals

C-Ray Therapeutics Partners with SHINE Technologies – Lu-177 Supply Agreement Targets China Radiopharmaceutical Market

Fineline Cube Mar 27, 2026
Company Deals

GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China’s Adult Self-Paid Market

Fineline Cube Mar 26, 2026
Policy / Regulatory

China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

Fineline Cube Mar 26, 2026
Company Drug

J&J’s Icotyde Sustains and Improves Complete Skin Clearance in Psoriasis Through 52 Weeks, Outperforming Deucravacitinib on Safety

Fineline Cube Mar 30, 2026
Company Drug

Takeda’s Zasocitinib Demonstrates Superior Efficacy Over Apremilast and Placebo in Phase III Psoriasis Trials with Unprecedented TYK2 Selectivity

Fineline Cube Mar 30, 2026
Company Medical Device

Microport EP Medtech’s EasyEcho ICE Catheter Wins NMPA Market Clearance

Fineline Cube Feb 2, 2026

Shanghai Microport EP Medtech Co., Ltd. (SHA: 688351) announced that the National Medical Products Administration...

Policy / Regulatory

NHSA Targets NRDL Fund Supervision in 2026 Crackdown

Fineline Cube Feb 2, 2026

China’s National Healthcare Security Administration (NHSA) this week issued the “Notice on Further Enhancing the...

Company

Regeneron Q4 Revenue Grows 3% to $3.9B on EYLEA HD and Dupixent Strength

Fineline Cube Feb 2, 2026

Regeneron Pharmaceuticals (NASDAQ: REGN) reported fourth‑quarter 2025 revenues of $3.884 billion , up 3% year‑on‑year (YOY), bringing...

Company Deals

Vcare Pharma Partners with Sun-Novo on VC005 JAK1 Inhibitor for Atopic Dermatitis

Fineline Cube Feb 2, 2026

Jiangsu Vcare PharmaTech Co., Ltd. announced a partnership with Beijing Sun-Novo Pharmaceutical Research Co., Ltd....

Company Drug

Sciwind’s Ecnoglutide Wins NMPA Nod as First cAMP‑Biased GLP‑1 Agonist

Fineline Cube Feb 2, 2026

Sciwind Biosciences Co., Ltd. announced that the National Medical Products Administration (NMPA) has approved ecnoglutide...

Policy / Regulatory

FDA Opens PreCheck Applications to Strengthen Domestic Drug Manufacturing

Fineline Cube Feb 2, 2026

The U.S. Food and Drug Administration this week began accepting applications for the FDA PreCheck...

Company Drug

Ab&b Bio-Tech’s Trivalent Influenza Vaccine Wins NMPA Nod for All Ages

Fineline Cube Feb 2, 2026

Ab&b Bio-Tech Co.,Ltd. (HKG: 2627) announced that the National Medical Products Administration (NMPA) has granted...

Company Drug

Sanofi Rezurock Wins EU Backing for Graft‑Versus‑Host Disease

Fineline Cube Feb 2, 2026

Sanofi (NASDAQ: SNY) announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human...

Company Drug

CMS-D017 Gets NMPA Nod for PNH Clinical Trial

Fineline Cube Feb 2, 2026

China Medical System Holdings (CMS; HKG: 0867) announced that the National Medical Products Administration (NMPA) has...

Company Drug

J&J AKEEGA Gets CHMP Nod for BRCA-Mutated Prostate Cancer

Fineline Cube Feb 2, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced that the Committee for Medicinal Products for Human Use...

Company Drug

Hengrui Ruitanning Gets NMPA Nod for Moderately Emetogenic Chemo Indication

Fineline Cube Feb 2, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the National Medical Products Administration (NMPA)...

Company Drug Policy / Regulatory

CDE Seeks Feedback on 103rd Batch of Generic Reference Preparations

Fineline Cube Feb 2, 2026

The Center for Drug Evaluation (CDE) is seeking industry feedback on the 103rd batch of...

Company Deals

Kyowa Kirin Reclaims Rocatinlimab Rights from Amgen in Strategic Shift

Fineline Cube Feb 2, 2026

Kyowa Kirin (TYO: 4151) announced it will cancel its licensing agreement with Amgen (NASDAQ: AMGN) for...

Company Drug

Chiesi Fabry Drug Pegunigalsidase Alfa Wins CHMP Backing for Extended Dosing

Fineline Cube Feb 2, 2026

Chiesi Group announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended...

Company

Novo Nordisk Appoints Yan Cai as Greater China President Amid LeadershipChange

Fineline Cube Feb 2, 2026

Novo Nordisk (NYSE: NVO) announced that Zhou Xiaping, Senior Vice President and President of Greater China,...

Company Drug

China Medical’s Opzelura Cream Gets NMPA Approval for Vitiligo

Fineline Cube Jan 30, 2026

China Medical System Holdings (CMS; HKG: 0867) announced that the National Medical Products Administration (NMPA) has...

Company Drug

Zhaoke Ophthalmology’s Yuvezzi Gets FDA Nod for Presbyopia

Fineline Cube Jan 30, 2026

Zhaoke Ophthalmology (HKG: 6622) announced that its UK partner Tenpoint Therapeutics has received FDA clearance...

Company Drug

CSPC’s SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials

Fineline Cube Jan 30, 2026

CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that the National Medical Products Administration (NMPA) has approved...

Company

AstraZeneca Commits $14.4B China Investment in Cell Therapy Push

Fineline Cube Jan 30, 2026

AstraZeneca (AZ, NASDAQ: AZN) announced a plan to invest RMB 100 billion (USD 14.4 billion) :in China by 2030 to...

Drug

Ascletis ASC40 Phase III Success in Acne Vulgaris

Fineline Cube Jan 30, 2026

Ascletis Pharma Inc (HKG: 1672) announced positive top‑line results from the open‑label Phase III study (NCT06248008)...

Posts pagination

1 … 25 26 27 … 642

Recent updates

  • J&J’s Icotyde Sustains and Improves Complete Skin Clearance in Psoriasis Through 52 Weeks, Outperforming Deucravacitinib on Safety
  • Takeda’s Zasocitinib Demonstrates Superior Efficacy Over Apremilast and Placebo in Phase III Psoriasis Trials with Unprecedented TYK2 Selectivity
  • Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond
  • Sinovac Biotech and Indonesia’s Bio Farma Forge Strategic Alliance to Expand Vaccine Access Across Developing Markets
  • RemeGen Posts 89% Revenue Surge in 2025, Returns to Profitability on Strength of Tai’ai and Disitamab Vedotin
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

J&J’s Icotyde Sustains and Improves Complete Skin Clearance in Psoriasis Through 52 Weeks, Outperforming Deucravacitinib on Safety

Company Drug

Takeda’s Zasocitinib Demonstrates Superior Efficacy Over Apremilast and Placebo in Phase III Psoriasis Trials with Unprecedented TYK2 Selectivity

Company Deals

Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond

Company Deals

Sinovac Biotech and Indonesia’s Bio Farma Forge Strategic Alliance to Expand Vaccine Access Across Developing Markets

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.